Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs

@article{Mastrodicasa2017LongAM,
  title={Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs},
  author={Mark A Mastrodicasa and Christopher A. Droege and Aaron M Mulhall and Neil E Ernst and R. Panos and M. A. Zafar},
  journal={Expert Opinion on Investigational Drugs},
  year={2017},
  volume={26},
  pages={161 - 174}
}
  • Mark A Mastrodicasa, Christopher A. Droege, +3 authors M. A. Zafar
  • Published 2017
  • Medicine
  • Expert Opinion on Investigational Drugs
    • ABSTRACT Introduction: Long acting muscarinic receptor antagonists (LAMA) reverse airflow obstruction by antagonizing para-sympathetic bronchoconstricting effects within the airways. For years, tiotropium, has been the cornerstone LAMA for chronic obstructive pulmonary disease (COPD) management. Recently, new agents, aclidinium bromide, glycopyrronium bromide, and umeclidinium bromide, have been developed and introduced into clinical practice. Areas covered: This article reviews the clinical… CONTINUE READING
    View on Taylor & Francis
    ncbi.nlm.nih.gov
    13 Citations
    Background Citations
    5
    13 Citations
    Citation Type

    Citation Type

    Revefenacin for the treatment of chronic obstructive pulmonary disease
    • 1
    Emerging muscarinic receptor antagonists for the treatment of asthma
    Pharmacology and Therapeutics of Bronchodilators Revisited
    • 20
    • PDF
    Revefenacin for the treatment of chronic obstructive pulmonary disease
    Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease
    • 2
    An overview of glycopyrrolate/eFlow® CS in COPD
    • 4
    Safety, Tolerability and Pharmacokinetics of Bencycloquidium Bromide, a Novel Inhaled Anticholinergic Bronchodilator, in Healthy Subjects: Results from Phase I Studies.
    • Z. Luo, Chao Hu, +4 authors Maozhi Liang
    • Medicine
    • European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
    • 2020
    Discovery of Novel Potent Muscarinic M3 Receptor Antagonists with Proper Plasma Stability by Structural Recombination of Marketed M3 Antagonists
    • 1
    Efficacy of budesonide/formoterol and tiotropium combination for the treatment of Chinese patients with chronic obstructive pulmonary disease
    • 3
    Acetylcholine signaling system in progression of lung cancers
    • 18

    References

    SHOWING 1-10 OF 69 REFERENCES
    Long-acting muscarinic receptor antagonists for the treatment of respiratory disease.
    • 56
    Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends.
    • 55
    Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease.
    • 66
    Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis
    • 29
    • PDF
    An oral selective M3 cholinergic receptor antagonist in COPD
    • 17
    • PDF
    Long-acting muscarinic antagonists for the prevention of exacerbations of chronic obstructive pulmonary disease
    • P. Jones
    • Medicine
    • Therapeutic advances in respiratory disease
    • 2015
    • 12
    Muscarinic receptor subtypes in airways.
    • 107
    Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    • 100
    • PDF
    V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results
    • 8
    • Highly Influential
    • PDF
    An update on bronchodilators in Phase I and II clinical trials
    • 36